Bambusa Therapeutics

BBTX
16.1550.40% ( +0.065 )
Trading: Nov 16, 12:28:01 (EDT)

Profile

About

Bambusa Therapeutics
Bambusa Therapeutics
BBTX.US

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis. It also develops BBT002, a long-acting bispecific antibody for respiratory and other Type 2 inflammatory diseases. Additionally, the company develops BBT003, a long-acting bispecific antibody for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.

Profile

Company Name
Bambusa Therapeutics, Inc.
Market
NasdaqGS
Founded
Industry
--
Fiscal Year End
--

Related Securities

Industry

Management